Slovakia has adopted an amendment to Act No. 363/2011, regulating, among other things, drug reimbursement and is undergoing a significant change in the availability of innovative treatments for patients. High expectations are associated with arrangements related to performance-based managed entry agreements. Opinions and positions towards this change appear to be inconsistent, and for the further application of the law in practice and when setting up the main implementation processes, it is necessary to understand the positions and opinions of the individual actors who are involved in the PB-MEA process. The interviews were conducted in the period from 20 May to 15 August 2022 around the same time as the finalisation of the amendment to Act No. 363/2011 and its adoption. A roughly one-hour open interview was conducted on a sample of 12 stakeholders in the following groups: representatives of the Ministry of Health, health-care providers, pharmaceutical companies and others, including a health insurance company. The main objective was to qualitatively describe the perception of this topic by key stakeholders in Slovakia. The responses were analysed using MAXQDATA 2022 software to obtain codes associated with key expressions. We identified three main strong top categories of expressions that strongly dominated the pro-management interviews with stakeholders: legislation, opportunities and threats. Ambiguity and insufficient coverage of the new law, improved availability of medicinal products and threats associated with data, IT systems and potentially unfavourable new reimbursement schemes were identified as key topics of each of the said top categories, respectively. Among individual sets of respondents, there is frequent consensus on both opportunities and threats in the area of implementing process changes in PB-MEA. For the successful implementation of the law in practice, some basic threats need to be removed, among which in particular is insufficient data infrastructure.

Department of Biomedical Technology Faculty of Biomedical Engineering Czech Technical University Prague 272 01 Kladno Czech Republic

Department of Public Health Faculty of Health and Social Work Trnava University 917 01 Trnava Slovakia

See more in PubMed

Wenzl M., Chapman A.S. Performance-Based Managed Entry Agreements for New Medicines in OECD Countries and EU Member States: How They Work and Possible Improvements Going forward. OECD; Paris, France: 2019. OECD Health Working Papers.

Psenkova M.B., Visnansky M., Mackovicova S., Tomek M. Drug Policy in Slovakia. Value Health Reg. Issues. 2017;13:44–49. doi: 10.1016/j.vhri.2017.07.002. PubMed DOI

Lehocká A., Kocková S., Matúš M. Novela zákona č. 363/2011—Navrhované zmeny a ich dopad na opravu DPH v súvislosti so spätnými platbami voči zdravotným poisťovniam. EY. Apr 26, 2022.

Klemp M., Frønsdal K.B., Facey K. What principles should govern the use of managed entry agreements? Int. J. Technol. Assess. Health Care. 2011;27:77–83. doi: 10.1017/S0266462310001297. PubMed DOI

Andersson E., Svensson J., Persson U., Lindgren P. Risk sharing in managed entry agreements—A review of the Swedish experience. Health Policy. 2020;124:404–410. doi: 10.1016/j.healthpol.2020.02.002. PubMed DOI

Bouvy J.C., Sapede C., Garner S. Managed Entry Agreements for Pharmaceuticals in the Context of Adaptive Pathways in Europe. Front. Pharmacol. 2018;9:280. doi: 10.3389/fphar.2018.00280. PubMed DOI PMC

Dabbous M., Chachoua L., Caban A., Toumi M. Managed Entry Agreements: Policy Analysis from the European Perspective. Value Health. 2020;23:425–433. doi: 10.1016/j.jval.2019.12.008. PubMed DOI

Ferrario A., Kanavos P. Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Soc. Sci. Med. 2015;124:39–47. doi: 10.1016/j.socscimed.2014.11.003. PubMed DOI

Lu C.Y., Lupton C., Rakowsky S., Babar Z.-U., Ross-Degnan D., Wagner A.K. Patient access schemes in Asia-pacific markets: Current experience and future potential. J. Pharm. Policy Pract. 2015;8:1–12. doi: 10.1186/s40545-014-0019-x. PubMed DOI PMC

Carlson J.J., Chen S., Garrison L.P. Performance-Based Risk-Sharing Arrangements: An Updated International Review. Pharmacoeconomics. 2017;35:1063–1072. doi: 10.1007/s40273-017-0535-z. PubMed DOI

Yeung K., Li M., Carlson J.J. Using Performance-Based Risk-Sharing Arrangements to Address Uncertainty in Indication-Based Pricing. J. Manag. Care Speéc. Pharm. 2017;23:1010–1015. doi: 10.18553/jmcp.2017.23.10.1010. PubMed DOI PMC

Kim A.E., Choi D.H., Chang J., Kim S.H. Performance-Based Risk-Sharing Arrangements (PBRSA): Is it a Solution to Increase Bang for the Buck for Pharmaceutical Reimbursement Strategy for Our Nation and Around the World? Clin. Drug Investig. 2020;40:1107–1113. doi: 10.1007/s40261-020-00972-w. PubMed DOI PMC

Di Giuseppe L.A., Buela G., Hereter J.B.Z., Terrasa S.A., Garfi L.G., Soriano E.R. Experience of a Performance-Based Risk-Sharing Arrangement for the Treatment of Rheumatoid Arthritis with Certolizumab Pegol. Value Health Reg. Issues. 2020;21:201–204. doi: 10.1016/j.vhri.2020.01.002. PubMed DOI

Ferrario A., Arāja D., Bochenek T., Čatić T., Dankó D., Dimitrova M., Fürst J., Greičiūtė-Kuprijanov I., Hoxha I., Jakupi A., et al. The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications. Pharmacoeconomics. 2017;35:1271–1285. doi: 10.1007/s40273-017-0559-4. PubMed DOI PMC

Kanavos P., Ferrario A., Tafuri G., Siviero P. Managing Risk and Uncertainty in Health Technology Introduction: The Role of Managed Entry Agreements. Glob. Policy. 2017;8:84–92. doi: 10.1111/1758-5899.12386. DOI

Toumi M., Jarosławski S., Sawada T., Kornfeld Å. The Use of Surrogate and Patient-Relevant Endpoints in Outcomes-Based Market Access Agreements. Appl. Health Econ. Health Policy. 2016;15:5–11. doi: 10.1007/s40258-016-0274-x. PubMed DOI

Pauwels K., Huys I., Vogler S., Casteels M., Simoens S. Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future. Front. Pharmacol. 2017;8:171. doi: 10.3389/fphar.2017.00171. PubMed DOI PMC

Palinkas L.A., Horwitz S.M., Green C.A., Wisdom J.P., Duan N., Hoagwood K. Purposeful Sampling for Qualitative Data Collection and Analysis in Mixed Method Implementation Research. Adm. Policy Ment. Health Ment. Health Serv. Res. 2015;42:533–544. doi: 10.1007/s10488-013-0528-y. PubMed DOI PMC

Wallace L.S. A View of Health Care Around the World. Ann. Fam. Med. 2013;11:84. doi: 10.1370/afm.1484. PubMed DOI PMC

Kapalla M., Kapallová D., Turecký L. An overview of the healthcare system in the Slovak Republic. EPMA J. 2010;1:549–561. doi: 10.1007/s13167-010-0061-y. PubMed DOI PMC

European Parliament Regulation of the European Parliament and the Council (EC) No 1394/2007 of November 13, 2007 on Drugs for Innovative Treatment, Amending Directive 2001/83/EC and Regulation (EC) No. 726/2004 (OJ L 324, 10 December 2007) as Amended. B.m.: Regulation of the European Parliament and the Council (EC) No. 1394/2007 of November 13, 2007. [(accessed on 12 April 2023)]. Available online: https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=celex%3A32007R1394.

European Parliament Regulation of the European Parliament and the Council (EC) No. 141/2000 of 16 December 1999 on Drugs for Rare Diseases (OJ L 18, 22.1. 2000; Special Edition of the OJ, Chap. 15/Vol. 5) as Amended. B.m.: OJ L 18, 22.1. 2000; Special Edition of the OJ, Chap. 15/Vol. 5. 1999. [(accessed on 12 April 2023)]. Available online: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32000R0141.

Makady A., van Acker S., Nijmeijer H., de Boer A., Hillege H., Klungel O., Goettsch W. Conditional Financing of Drugs in the Netherlands: Past, Present, and Future—Results from Stakeholder Interviews. Value Health. 2019;22:399–407. doi: 10.1016/j.jval.2018.11.016. PubMed DOI

Cluley V., Ziemann A., Feeley C., Olander E.K., Shamah S., Stavropoulou C., Bsc S.S. Mapping the role of patient and public involvement during the different stages of healthcare innovation: A scoping review. Health Expect. 2022;25:840–855. doi: 10.1111/hex.13437. PubMed DOI PMC

Finn V., Stephenson J., Astin F. Patient preferences for involvement in health service development. Br. J. Nurs. 2018;27:1004–1010. doi: 10.12968/bjon.2018.27.17.1004. PubMed DOI

Stakeholder Insights into Czech Performance-Based Managed Entry Agreements: Potential for Transformative Change in Pharmaceutical Access?